|
1.
|
Sirica AE: Cholangiocarcinoma: molecular
targeting strategies for chemoprevention and therapy. Hepatology.
41:5–15. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Sriamporn S, Pisani P, Pipitgool V,
Suwanrungruang K, Kamsaard S and Parkin DM: Prevalence of
Opisthorchis viverrini infection and incidence of
cholangiocarcinoma in Khon Kaen, Northeast Thailand. Trop Med Int
Health. 9:588–594. 2004.
|
|
3.
|
Wise C, Pilanthananond M, Perry BF, Alpini
G, McNeal M and Glaser SS: Mechanisms of biliary carcinogenesis and
growth. World J Gastroenterol. 14:2986–2989. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Franco OE, Shaw AK, Strand DW and Hayward
SW: Cancer associated fibroblasts in cancer pathogenesis. Semin
Cell Dev Biol. 21:33–39. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Chuaysri C, Thuwajit P, Paupairoj A,
Chau-In S, Suthiphongchai T and Thuwajit C: Alpha-smooth muscle
actin-positive fibroblasts promote biliary cell proliferation and
correlate with poor survival in cholangiocarcinoma. Oncol Rep.
21:957–969. 2009.PubMed/NCBI
|
|
6.
|
Utispan K, Thuwajit P, Abiko Y, et al:
Gene expression profiling of cholangiocarcinoma-derived fibroblast
reveals alterations related to tumor progression and indicates
periostin as a poor prognostic marker. Mol Cancer. 9:132010.
View Article : Google Scholar
|
|
7.
|
Sirica AE, Campbell DJ and Dumur CI:
Cancer-associated fibroblasts in intrahepatic cholangiocarcinoma.
Curr Opin Gastroenterol. 27:276–284. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Terada T, Makimoto K, Terayama N, Suzuki Y
and Nakanuma Y: Alpha-smooth muscle actin-positive stromal cells in
cholangiocarcinomas, hepatocellular carcinomas and metastatic liver
carcinomas. J Hepatol. 24:706–712. 1996. View Article : Google Scholar
|
|
9.
|
Darby IA, Vuillier-Devillers K, Pinault E,
et al: Proteomic analysis of differentially expressed proteins in
peripheral cholangiocarcinoma. Cancer Microenviron. 4:73–91. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Dumur CI, Campbell DJ, DeWitt JL, Oyesanya
RA and Sirica AE: Differential gene expression profiling of
cultured neu-transformed versus spontaneously-transformed rat
cholangiocytes and of corresponding cholangiocarcinomas. Exp Mol
Pathol. 89:227–235. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Ruan K, Bao S and Ouyang G: The
multifaceted role of periostin in tumorigenesis. Cell Mol Life Sci.
66:2219–2230. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Erkan M, Kleeff J, Gorbachevski A, et al:
Periostin creates a tumor-supportive microenvironment in the
pancreas by sustaining fibrogenic stellate cell activity.
Gastroenterology. 132:1447–1464. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Fukushima N, Kikuchi Y, Nishiyama T, Kudo
A and Fukayama M: Periostin deposition in the stroma of invasive
and intraductal neoplasms of the pancreas. Mod Pathol.
21:1044–1053. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Li JS, Sun GW, Wei XY and Tang WH:
Expression of periostin and its clinicopathological relevance in
gastric cancer. World J Gastroenterol. 13:5261–5266. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Puglisi F, Puppin C, Pegolo E, et al:
Expression of periostin in human breast cancer. J Clin Pathol.
61:494–498. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Puppin C, Fabbro D, Dima M, et al: High
periostin expression correlates with aggressiveness in papillary
thyroid carcinomas. J Endocrinol. 197:401–408. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Takanami I, Abiko T and Koizumi S:
Expression of periostin in patients with non-small cell lung
cancer: correlation with angiogenesis and lymphangiogenesis. Int J
Biol Markers. 23:182–186. 2008.PubMed/NCBI
|
|
18.
|
Gillan L, Matei D, Fishman DA, Gerbin CS,
Karlan BY and Chang DD: Periostin secreted by epithelial ovarian
carcinoma is a ligand for alpha(V)beta(3) and alpha(V)beta(5)
integrins and promotes cell motility. Cancer Res. 62:5358–5364.
2002.PubMed/NCBI
|
|
19.
|
Kudo Y, Ogawa I, Kitajima S, et al:
Periostin promotes invasion and anchorage-independent growth in the
metastatic process of head and neck cancer. Cancer Res.
66:6928–6935. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Bao S, Ouyang G, Bai X, et al: Periostin
potently promotes metastatic growth of colon cancer by augmenting
cell survival via the Akt/PKB pathway. Cancer Cell. 5:329–339.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Baril P, Gangeswaran R, Mahon PC, et al:
Periostin promotes invasiveness and resistance of pancreatic cancer
cells to hypoxia-induced cell death: role of the beta4 integrin and
the PI3k pathway. Oncogene. 26:2082–2094. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Li G, Jin R, Norris RA, et al: Periostin
mediates vascular smooth muscle cell migration through the
integrins alphavbeta3 and alphavbeta5 and focal adhesion kinase
(FAK) pathway. Atherosclerosis. 208:358–365. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Shao R, Bao S, Bai X, et al: Acquired
expression of periostin by human breast cancers promotes tumor
angiogenesis through up-regulation of vascular endothelial growth
factor receptor 2 expression. Mol Cell Biol. 24:3992–4003. 2004.
View Article : Google Scholar
|
|
24.
|
Yan W and Shao R: Transduction of a
mesenchyme-specific gene periostin into 293T cells induces cell
invasive activity through epithelial-mesenchymal transformation. J
Biol Chem. 281:19700–19708. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Sripa B, Leungwattanawanit S, Nitta T, et
al: Establishment and characterization of an
opisthorchiasis-associated cholangiocarcinoma cell line (KKU-100).
World J Gastroenterol. 11:3392–3397. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Maruyama M, Kobayashi N, Westerman KA, et
al: Establishment of a highly differentiated immortalized human
cholangiocyte cell line with SV40T and hTERT. Transplantation.
77:446–451. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Gahmberg CG, Fagerholm SC, Nurmi SM,
Chavakis T, Marchesan S and Gronholm M: Regulation of integrin
activity and signalling. Biochim Biophys Acta. 1790:431–444. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Angeli F, Koumakis G, Chen MC, Kumar S and
Delinassios JG: Role of stromal fibroblasts in cancer: promoting or
impeding? Tumour Biol. 30:109–120. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Qiu W, Hu M, Sridhar A, et al: No evidence
of clonal somatic genetic alterations in cancer-associated
fibroblasts from human breast and ovarian carcinomas. Nat Genet.
40:650–655. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Pietras K and Ostman A: Hallmarks of
cancer: interactions with the tumor stroma. Exp Cell Res.
316:1324–1331. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Gonda TA, Varro A, Wang TC and Tycko B:
Molecular biology of cancer-associated fibroblasts: can these cells
be targeted in anti-cancer therapy? Semin Cell Dev Biol. 21:2–10.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Rasanen K and Vaheri A: Activation of
fibroblasts in cancer stroma. Exp Cell Res. 316:2713–2722. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Rosenthal E, McCrory A, Talbert M, Young
G, Murphy-Ullrich J and Gladson C: Elevated expression of TGF-beta1
in head and neck cancer-associated fibroblasts. Mol Carcinog.
40:116–121. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
34.
|
Paland N, Kamer I, Kogan-Sakin I, Madar S,
Goldfinger N and Rotter V: Differential influence of normal and
cancer-associated fibroblasts on the growth of human epithelial
cells in an in vitro cocultivation model of prostate cancer. Mol
Cancer Res. 7:1212–1223. 2009. View Article : Google Scholar
|
|
35.
|
Volpes R, van den Oord JJ and Desmet VJ:
Integrins as differential cell lineage markers of primary liver
tumors. Am J Pathol. 142:1483–1492. 1993.PubMed/NCBI
|
|
36.
|
Enjoji M, Sakai H, Nakashima M and Nawata
H: Integrins: utility as cell type- and stage-specific markers for
hepatocellular carcinoma and cholangiocarcinoma. In Vitro Cell Dev
Biol Anim. 34:25–27. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
37.
|
Patsenker E, Wilkens L, Banz V, et al: The
alphavbeta6 integrin is a highly specific immunohistochemical
marker for cholangiocarcinoma. J Hepatol. 52:362–369. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
38.
|
Hynes RO: Integrins: bidirectional,
allosteric signaling machines. Cell. 110:673–687. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
39.
|
Ouyang G, Liu M, Ruan K, Song G, Mao Y and
Bao S: Upregulated expression of periostin by hypoxia in
non-small-cell lung cancer cells promotes cell survival via the
Akt/PKB pathway. Cancer Lett. 281:213–219. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
40.
|
Fresno Vara JA, Casado E, de Castro J,
Cejas P, Belda-Iniesta C and Gonzalez-Baron M: PI3K/Akt signalling
pathway and cancer. Cancer Treat Rev. 30:193–204. 2004.PubMed/NCBI
|
|
41.
|
Sarker D, Reid AH, Yap TA and de Bono JS:
Targeting the PI3K/AKT pathway for the treatment of prostate
cancer. Clin Cancer Res. 15:4799–4805. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
42.
|
Yadav V and Denning MF: Fyn is induced by
Ras/PI3K/Akt signaling and is required for enhanced
invasion/migration. Mol Carcinog. 50:346–352. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
43.
|
Roman J, Ritzenthaler JD, Roser-Page S,
Sun X and Han S: alpha5beta1-integrin expression is essential for
tumor progression in experimental lung cancer. Am J Respir Cell Mol
Biol. 43:684–691. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
44.
|
Mierke CT, Frey B, Fellner M, Herrmann M
and Fabry B: Integrin alpha5beta1 facilitates cancer cell invasion
through enhanced contractile forces. J Cell Sci. 124:369–383. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
45.
|
Morozevich G, Kozlova N, Cheglakov I,
Ushakova N and Berman A: Integrin alpha5beta1 controls invasion of
human breast carcinoma cells by direct and indirect modulation of
MMP-2 collagenase activity. Cell Cycle. 8:2219–2225. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
46.
|
Castillo SS, Brognard J, Petukhov PA, et
al: Preferential inhibition of Akt and killing of Akt-dependent
cancer cells by rationally designed phosphatidylinositol ether
lipid analogues. Cancer Res. 64:2782–2792. 2004. View Article : Google Scholar
|
|
47.
|
Kyutoku M, Taniyama Y, Katsuragi N, et al:
Role of periostin in cancer progression and metastasis: inhibition
of breast cancer progression and metastasis by anti-periostin
antibody in a murine model. Int J Mol Med. 28:181–186.
2011.PubMed/NCBI
|
|
48.
|
Almokadem S and Belani CP: Volociximab in
cancer. Expert Opin Biol Ther. 12:251–257. 2012. View Article : Google Scholar
|
|
49.
|
Li Z, Tan F, Liewehr DJ, Steinberg SM and
Thiele CJ: In vitro and in vivo inhibition of neuroblastoma tumor
cell growth by AKT inhibitor perifosine. J Natl Cancer Inst.
102:758–770. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
50.
|
Pal SK, Reckamp K, Yu H and Figlin RA: Akt
inhibitors in clinical development for the treatment of cancer.
Expert Opin Investig Drugs. 19:1355–1366. 2010. View Article : Google Scholar : PubMed/NCBI
|
